SNP
|
CHR:Position(bp)a
|
Geneb
|
Coded allele
|
Non-coded allele
|
Facial traits
|
Association results
| |
Meta-analysis (Phase 1 + 2)
|
---|
|
AF
|
beta ± se
|
P-value
| |
beta ± se
|
P-value
|
Q
|
I2
|
---|
rs7567283
|
2:19,595,772
|
OSR1-WDR35
|
G
|
A
|
Right facial angle of en-ex-go
|
Phase 1
|
0.24
|
−0.572 ± 0.109
|
1.72 × 10−7
| |
− 0.536 ± 0.096
|
2.75 × 10
−8
|
0.48
|
0.00
|
Phase 2
|
0.24
|
− 0.410 ± 0.205
|
0.046
| | | | | |
rs970797
|
2:176,820,065
|
HOXD1-MTX2
|
A
|
C
|
Tangent line angle of el3
|
Phase 1
|
0.33
|
0.017 ± 0.003
|
4.90 × 10
−8
| |
0.015 ± 0.003
|
7.40 × 10
−9
|
0.29
|
12.52
|
Phase 2
|
0.34
|
0.011 ± 0.005
|
0.030
| | | | | |
Tangent line angle of er3
|
Phase 1
|
0.33
|
0.015 ± 0.003
|
4.51 × 10−7
| |
0.015 ± 0.003
|
3.97 × 10
− 9
|
0.93
|
0.00
|
Phase 2
|
0.34
|
0.014 ± 0.005
|
0.003
| | | | | |
rs3736712
|
6:169,699,889
|
WDR27
|
C
|
T
|
Eye tail length
|
Phase 1
|
0.37
|
0.322 ± 0.055
|
5.89 × 10
−9
| |
0.293 ± 0.048
|
8.44 × 10
−10
|
0.30
|
6.92
|
Phase 2
|
0.38
|
0.208 ± 0.095
|
0.029
| | | | | |
rs2193054
|
17:67,537,404
|
SOX9
|
C
|
G
|
Profile nasal angle
|
Phase 1
|
0.47
|
−0.007 ± 0.001
|
1.43 × 10
−11
| |
−0.007 ± 0.001
|
6.17 × 10
− 17
|
0.22
|
33.67
|
Phase 2
|
0.46
|
−0.009 ± 0.002
|
4.60 × 10− 7
| | | | | |
Nasal tip protrusion
|
Phase 1
|
0.47
|
0.019 ± 0.003
|
1.93 × 10
−8
| |
0.017 ± 0.003
|
5.34 × 10
−9
|
0.23
|
31.80
|
Phase 2
|
0.46
|
0.011 ± 0.005
|
0.050
| | | | | |
rs2206437
|
20:37,426,155
|
DHX35
|
A
|
T
|
Subnasal width
|
Phase 1
|
0.26
|
−0.272 ± 0.054
|
4.75 × 10− 7
| |
− 0.283 ± 0.047
|
1.61 × 10
−9
|
0.69
|
0.00
|
Phase 2
|
0.28
|
− 0.316 ± 0.095
|
8.67 × 10−4
| | | | | |
- Bold and underlined text indicates genome-wide significant P values (5 × 10−8)
- CHR chromosome, AF coded allele frequency, Q P-value for Cochrane’s Q statistic, I2 heterogeneity index
- aPositions according to NCBI Build 36
- bGenes are defined as the gene within the SNP locates or genes closest to the SNP within a ±400-kb window when the SNP dose not locate within a gene